Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice
Authors:
- 1 March 2010
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 70 (5) , 573-603
Abstract
Proarrhythmia, the development of new or worse arrhythmias in response to drug therapy, is a major limitation to the development and use of new drugs. There are different types of drug-induced...Keywords
This publication has 328 references indexed in Scilit:
- A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channelAnalytical Biochemistry, 2009
- Risk stratification for sudden cardiac death: Is there a clinical role for T wave alternans?Heart Rhythm, 2009
- Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidineHeart Rhythm, 2008
- Prevalence of early-onset atrial fibrillation in congenital long QT syndromeHeart Rhythm, 2008
- Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndromeHeart Rhythm, 2008
- Assessing risk of a prolonged QT interval–a survey of emergency physiciansInternational Journal of Emergency Medicine, 2008
- Pharmacological approach to the treatment of long and short QT syndromesPharmacology & Therapeutics, 2008
- Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: Effects of ranolazineHeart Rhythm, 2007
- Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmiasHeart Rhythm, 2006
- Long QT syndromes and torsade de pointesThe Lancet, 1999